Clinical Trial Update: Alectinib in Combination With Bevacizumab in ALK Positive NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alectinib in combination with bevacizumab for ALK-positive non-squamous non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Instituto Nacional de Cancerologia de Mexico | Conditions: ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung | Phase 2 | Status: COMPLETED